AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Samsara, you need to believe its connected operations cloud and AI features can sustain strong recurring revenue while growing into a very large addressable market. The upcoming Q2 FY2027 earnings call is the next key catalyst, because it will show whether recent ARR momentum and AI adoption still support a premium-priced stock. This event does not materially change the biggest near term risk, which remains whether that premium valuation is sustainable.
The most relevant recent announcement here is Samsara’s June 4 Q1 FY2026 update, where it became GAAP profitable and guided FY2027 revenue to about US$2.0 billion. That guidance underpins bullish views that strong ARR growth and improving margins can support today’s valuation, but it also frames the bar the company must meet or beat on September 3. Any shift to that outlook could quickly influence how investors think about both growth and price.
Yet beneath the optimism, there is growing concern that intensifying competition and OEM integrations could quietly undercut Samsara’s pricing power, a risk investors should be aware of...
Read the full narrative on Samsara (it's free!)
Samsara's narrative projects $2.8 billion revenue and $228.5 million earnings by 2029.
Uncover how Samsara's forecasts yield a $44.17 fair value, a 16% upside to its current price.
Some of the lowest ranked analysts paint a much tougher picture than consensus, assuming revenue of about US$2.9 billion and earnings of roughly US$258 million by 2029, and highlighting OEM digitization as a direct threat to Samsara’s long term relevance.
Explore 7 other fair value estimates on Samsara - why the stock might be worth 9% less than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com